A Retrospective Study to Investigate Safety of Receiving Interleukin-17 Monoclonal Antibody for Psoriasis Patients With Hepatitis B Virus

IF 3.4 4区医学 Q1 DERMATOLOGY

Dermatologic Therapy Pub Date : 2025-02-27 DOI:10.1155/dth/8942831

Haohao Wu, Juan Wang, Min Zhang, Jing Peng, Yi You

{"title":"A Retrospective Study to Investigate Safety of Receiving Interleukin-17 Monoclonal Antibody for Psoriasis Patients With Hepatitis B Virus","authors":"Haohao Wu, Juan Wang, Min Zhang, Jing Peng, Yi You","doi":"10.1155/dth/8942831","DOIUrl":null,"url":null,"abstract":"<div>\n Background: The increasing utilization of interleukin-17 (IL-17) monoclonal antibody (MA) for psoriasis treatment, coupled with the high prevalence of hepatitis B virus (HBV), underscores the need for comprehensive safety data. This retrospective study aims to evaluate the safety of IL-17 MA treatment in psoriasis patients with concurrent HBV infection.\n Research Design and Methods: The study screened 531 psoriasis patients treated with IL-17 MA, ultimately enrolling 59 patients with abnormal HBV serological data. Outcomes assessed include HBV virological reactivation and changes in HBsAb serum quantification post-IL-17 MA therapy.\n Results: Laboratory data revealed HBV virological reactivation in two psoriasis patients classified as inactive HBV carriers (IBCs). Patients who had previously received HBV vaccination exhibited a significant decrease in HBsAb serum quantification following IL-17 MA therapy.\n Conclusion: IL-17 MA therapy presents a potential risk of HBV reactivation in psoriasis patients with HBV infection. Furthermore, IL-17 MA appears to weaken HBV resistance in vaccinated patients.\n </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.4000,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/8942831","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatologic Therapy","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1155/dth/8942831","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The increasing utilization of interleukin-17 (IL-17) monoclonal antibody (MA) for psoriasis treatment, coupled with the high prevalence of hepatitis B virus (HBV), underscores the need for comprehensive safety data. This retrospective study aims to evaluate the safety of IL-17 MA treatment in psoriasis patients with concurrent HBV infection.

Research Design and Methods: The study screened 531 psoriasis patients treated with IL-17 MA, ultimately enrolling 59 patients with abnormal HBV serological data. Outcomes assessed include HBV virological reactivation and changes in HBsAb serum quantification post-IL-17 MA therapy.

Results: Laboratory data revealed HBV virological reactivation in two psoriasis patients classified as inactive HBV carriers (IBCs). Patients who had previously received HBV vaccination exhibited a significant decrease in HBsAb serum quantification following IL-17 MA therapy.

Conclusion: IL-17 MA therapy presents a potential risk of HBV reactivation in psoriasis patients with HBV infection. Furthermore, IL-17 MA appears to weaken HBV resistance in vaccinated patients.

Abstract Image

查看原文本刊更多论文

乙型肝炎病毒银屑病患者接受白介素-17单克隆抗体治疗安全性的回顾性研究

背景：白介素-17 （IL-17）单克隆抗体（MA）在银屑病治疗中的应用日益增加，加上乙型肝炎病毒（HBV）的高流行率，强调了对综合安全性数据的需求。本回顾性研究旨在评估IL-17 MA治疗合并HBV感染的银屑病患者的安全性。研究设计与方法：本研究筛选了531例接受IL-17 MA治疗的银屑病患者，最终纳入了59例HBV血清学数据异常的患者。评估的结果包括HBV病毒学再激活和il -17 MA治疗后HBsAb血清定量的变化。结果：实验室数据显示两例被分类为非活动性HBV携带者（IBCs）的银屑病患者HBV病毒学再激活。先前接受过HBV疫苗接种的患者在IL-17 MA治疗后HBsAb血清定量显着降低。结论：IL-17 MA治疗对HBV感染的银屑病患者存在HBV再激活的潜在风险。此外，IL-17 MA似乎减弱了接种疫苗患者的HBV耐药性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Dermatologic Therapy 医学-皮肤病学

CiteScore

7.00

自引率

8.30%

发文量

711

审稿时长

3 months

期刊介绍： Dermatologic Therapy has been created to fill an important void in the dermatologic literature: the lack of a readily available source of up-to-date information on the treatment of specific cutaneous diseases and the practical application of specific treatment modalities. Each issue of the journal consists of a series of scholarly review articles written by leaders in dermatology in which they describe, in very specific terms, how they treat particular cutaneous diseases and how they use specific therapeutic agents. The information contained in each issue is so practical and detailed that the reader should be able to directly apply various treatment approaches to daily clinical situations. Because of the specific and practical nature of this publication, Dermatologic Therapy not only serves as a readily available resource for the day-to-day treatment of patients, but also as an evolving therapeutic textbook for the treatment of dermatologic diseases.